Potential lncRNA diagnostic biomarkers for early gastric cancer

Lu, Qiong; Takata, Yasuyuki; Ou, Xilong; Cao, Dazhong; Xie, Ting; Chen, Xia

doi:10.3892/mmr.2017.7770

Cited by 33 publications

(17 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Long non-coding RNA (lncRNA) is known as a type of noncoding RNA with over 200 nucleotides in length and non-protein coding ability. 8 It has been certified that abnormal expression of lncRNAs plays a vital role in the progression of various cancers such as ovarian cancer, 9 colon cancer 10 and gastric cancer. 11 Therefore, studying lncRNAs may be of great value in exploring the occurrence and development of tumors.…”

mentioning

confidence: 99%

LncRNA HOXA11‐AS drives cisplatin resistance of human LUAD cells via modulating miR‐454‐3p/Stat3

et al. 2018

View full text Add to dashboard Cite

Over the past several years, long non‐coding RNAs (lncRNAs) have attracted more and more attention due to their special functions. They are vital biomarkers in multiple diseases. LncRNA HOMEOBOX A11 (HOXA11) has been found to be aberrantly expressed in some kinds of malignant tumors. In this study, we mainly discuss the oncogenic role of it in promoting malignant progression and chemoresistance in lung adenocarcinoma (LUAD) cells. The expression of HOXA11‐AS was much stronger in cisplatin‐resistant LUAD cells. Based on The Cancer Genome Atlas database, patients with high expression of HOXA11‐AS had shorter survival time. Additionally, knockdown of HOXA11‐AS caused positive changes in cell activities of LUAD. For example, cell proliferation and migration were weakened, the epithelial mesenchymal transition process was reversed, and apoptosis was induced. These changes were more obvious in cells treated with cisplatin. Next, the HOXA11‐AS/miR‐454‐3p/Stat3 (signal transducer and activator of transcription 3) pathway was found to influence the cisplatin resistance of LUAD cells. HOXA11‐AS specifically acted as a competing endogenous RNA (ceRNA) in LUAD cells. The combinations among these three genes were demonstrated. Finally, rescue assays were applied to demonstrate the ceRNA pattern consisting of HOXA11‐AS, miR‐454‐3p and Stat3. In conclusion, lncRNA HOXA11‐AS acted as a ceRNA to promote cisplatin resistance of human LUAD cells via the miR‐454‐3p/Stat3 axis.

show abstract

mentioning

confidence: 99%

LncRNA HOXA11‐AS drives cisplatin resistance of human LUAD cells via modulating miR‐454‐3p/Stat3

et al. 2018

View full text Add to dashboard Cite

show abstract

“…26 The AUC for EGC of XIST and RRP1B were reported to be 0.733 and 0.753, and the sensitivity and specificity were 0.846 and 0.590, and 0.859 and 0.564, respectively. 27,28 The specificity of serum p53 antibody for EGC diagnosis was as high as 99.15%, but the sensitivity was as low as 12.35%. 29 The sensitivity and specificity of serum pepsinogen and gastrin 17 in the diagnosis of EGC were 83% and 68%, respectively.…”

Section: Discussionmentioning

confidence: 99%

<p>Evaluation of C5orf66-AS1 as a Potential Biomarker for Predicting Early Gastric Cancer and Its Role in Gastric Carcinogenesis</p>

Zhou

Jing

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Long non-coding RNAs (lncRNAs) participate in a series of pathological processes in tumorigenesis. Reports show that C5orf66-AS1, an antisense lncRNA, is expressed in various tumors. However, the role of C5orf66-AS1 in gastric cancer (GC) has not been fully clarified. The study focused on the expression patterns and serum level of C5orf66-AS1 in GC to explore its potential application in GC screening and diagnosis. The effects of C5orf66-AS1 on GC cells were also analyzed. Methods: Tissue and serum samples were used for RNA isolation. Expression levels of C5orf66-AS1 in GC tissues, serum, and cell lines were detected using quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR). CCK-8, transwell, and wound healing assays were performed to determine the effects of C5orf66-AS1 on GC cell behavior. Results: C5orf66-AS1 expression was downregulated in GC cells compared to that in adjacent normal tissues. Serum C5orf66-AS1 levels were significantly lower in GC patients than in superficial gastritis (GS) and atrophic gastritis (GA) patients. Low serum expression of C5orf66-AS1 was associated with an increased risk of gastric dysplasia (GD) and GC. Receiver operating characteristic curve results showed that the area under curve (AUC) for GC was 0.688, with a sensitivity and specificity of 77.5% and 53.6%, respectively. For the GD + early gastric cancer (ECG) group, the AUC was 0.789, with a sensitivity and specificity of 85.15% and 62.86%, respectively. Correlation analyses of clinicopathological parameters showed that serum C5orf66-AS1 was predominantly associated with Lauren type, TNM stages, pTNM stages, and vessel tumor emboli. Additionally, in vitro overexpression of C5orf66-AS1 in AGS cells inhibited cell proliferation, migration, and invasion. Conclusion: Decreased expression levels of serum C5orf66-AS1 can be utilized for diagnosis of GC, especially for early diagnosis. The low level of serum C5orf66-AS1 indicated poor biological behavior of tumors in GC patients. In addition, C5orf66-AS1 can inhibit GC cell proliferation, migration, and invasion.

show abstract

“…H19 in plasma enabled the discrimination of early-stage Gc from controls with an AUc of 0.877 (93). Lu et al (105) also developed a panel of five lncRNAs in tumor tissues with high values of early diagnosis, which helps to identify indistinguishable focus in endoscopy. The single nucleotide polymorphism (SNP) rs4759314, which contributes to a genotype-specific effect on the expression of the host gene HOTAIR, has been shown to be closely associated with the risk of developing Gc in chinese populations (106).…”

Section: Long Non-coding Rnas (Lncrnas)mentioning

confidence: 99%

Role of circular RNAs and long non‑coding RNAs in the clinical translation of gastric cancer (Review)

et al. 2020

View full text Add to dashboard Cite

Gastric cancer (Gc) is a malignancy with high incidence and mortality rates worldwide. It has a severe impact on patients diagnosed and on society. With the rapid development of bioinformatics and detection technologies, non-coding RNAs have been demonstrated to play important roles in gastric carcinogenesis, including circular RNAs (circRNAs) and long non-coding RNAs (lncRNAs). Previous studies have indicated that these two types of RNAs with notable characteristics can serve as promising biomarkers for clinical diagnosis and prognosis. The identification of relevant mechanisms has revealed the immense potential of circRNAs and lncRNAs in the treatment of Gc. However, there are still numerous issues that need to be resolved. The present review focuses on the clinical translation of circRNAs and lncRNAs into Gc. Important achievements and currently existing limitations in this field of research are summarized from recent studies. The present review also proposes serviceable suggestions for further development.

show abstract

Potential lncRNA diagnostic biomarkers for early gastric cancer

Cited by 33 publications

References 39 publications

LncRNA HOXA11‐AS drives cisplatin resistance of human LUAD cells via modulating miR‐454‐3p/Stat3

LncRNA HOXA11‐AS drives cisplatin resistance of human LUAD cells via modulating miR‐454‐3p/Stat3

<p>Evaluation of C5orf66-AS1 as a Potential Biomarker for Predicting Early Gastric Cancer and Its Role in Gastric Carcinogenesis</p>

Role of circular RNAs and long non‑coding RNAs in the clinical translation of gastric cancer (Review)

Contact Info

Product

Resources

About